Kane Biotech (CVE:KNE) Hits New 52-Week Low – Time to Sell?

Kane Biotech Inc. (CVE:KNE) reached a new 52-week low on Friday . The stock traded as low as C$0.03 and last traded at C$0.03, with a volume of 226000 shares. The stock had previously closed at C$0.04.

Kane Biotech Price Performance

The firm has a 50 day simple moving average of C$0.03 and a two-hundred day simple moving average of C$0.04. The company has a quick ratio of 0.39, a current ratio of 0.68 and a debt-to-equity ratio of -308.66. The stock has a market capitalization of C$6.36 million, a P/E ratio of -0.44 and a beta of 1.04.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.